Search

Displaying results 4321 - 4330 of 6951 in total
  1. Drug

    BMS-863233

    go.drugbank.com/drugs/DB12357
    Investigational

    BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.

  2. Drug

    Oglemilast

    go.drugbank.com/drugs/DB12375
    Investigational

    Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.

  3. Drug

    Lisofylline

    go.drugbank.com/drugs/DB12406
    Investigational

    Lisofylline has been investigated for the treatment of Type 1 Diabetes Mellitus.

  4. Drug

    Methyl pyrrolidone

    go.drugbank.com/drugs/DB12521
    Investigational

    N Methyl Pyrrolidone is under investigation for the treatment of Multiple Myeloma.

  5. Drug

    GSK-1292263

    go.drugbank.com/drugs/DB12627
    Investigational

    GSK1292263 has been investigated for the treatment of DIABETES MELLITUS, TYPE 2.

  6. Drug

    Farletuzumab

    go.drugbank.com/drugs/DB05595
    Investigational

    Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

  7. Drug

    Dimethyl sulfone

    go.drugbank.com/drugs/DB14090
    Investigational

    Mixtures: Conart-MSM Sachet for Oral Solution, Condrosa-MSM Sachet for Oral Solution
  8. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments

  9. Drug

    Cetuximab sarotalocan

    go.drugbank.com/drugs/DB19240
    Investigational

    ) for the treatment of Recurrent Head/Neck Cancer. … Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

  10. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]